187 related articles for article (PubMed ID: 37275355)
1. The urgency to expand the antiviral indications of general chronic hepatitis B patients.
Fan P; Li LQ; Chen EQ
Front Med (Lausanne); 2023; 10():1165891. PubMed ID: 37275355
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
3. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of chronic hepatitis B phases in Eritrean patients: a laboratory-based cross-sectional study.
Hamida ME; Raja SM; Seyoum Y; Elkhidir IM; Tekle F
BMC Gastroenterol; 2021 May; 21(1):198. PubMed ID: 33933017
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
[No Abstract] [Full Text] [Related]
6. [Natural history and disease progression of chronic hepatitis B virus infection].
Wang LJ; Li MW; Liu YN; Chen XM; Zhao JM; Liu SH; Lu FM
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):920-926. PubMed ID: 36241234
[TBL] [Abstract][Full Text] [Related]
7. Designing immune therapy for chronic hepatitis B.
Fazle Akbar SM; Al-Mahtab M; Hiasa Y
J Clin Exp Hepatol; 2014 Sep; 4(3):241-6. PubMed ID: 25755566
[TBL] [Abstract][Full Text] [Related]
8. Update on hepatitis B virus infection.
You CR; Lee SW; Jang JW; Yoon SK
World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
[TBL] [Abstract][Full Text] [Related]
9. Effect of Antiviral Therapy During Pregnancy on Natural Killer Cells in Pregnant Women With Chronic HBV Infection.
Wang F; Xie S; Ran C; Hao H; Jiang T; Deng W; Bi X; Lin Y; Yang L; Sun F; Zeng Z; Xie Y; Li M; Yi W
Front Immunol; 2022; 13():893628. PubMed ID: 35677040
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study.
Wei S; Hu M; Chen H; Xie Q; Wang P; Li H; Peng J
BMC Gastroenterol; 2022 Aug; 22(1):387. PubMed ID: 35978283
[TBL] [Abstract][Full Text] [Related]
11. Multifaceted Defects in Monocytes in Different Phases of Chronic Hepatitis B Virus Infection: Lack of Restoration after Antiviral Therapy.
Dey D; Pal S; Chakraborty BC; Baidya A; Bhadra S; Ghosh R; Banerjee S; Ahammed SKM; Chowdhury A; Datta S
Microbiol Spectr; 2022 Dec; 10(6):e0193922. PubMed ID: 36445121
[TBL] [Abstract][Full Text] [Related]
12. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment.
Juday T; Tang H; Harris M; Powers AZ; Kim E; Hanna GJ
J Gen Intern Med; 2011 Mar; 26(3):239-44. PubMed ID: 20978862
[TBL] [Abstract][Full Text] [Related]
13. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
Wong GL; Chan HL; Tse YK; Yip TC; Lam KL; Lui GC; Wong VW
J Hepatol; 2018 Oct; 69(4):793-802. PubMed ID: 29758335
[TBL] [Abstract][Full Text] [Related]
14. Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA.
Zhou J; Wang F; Li L; Chen E
Precis Clin Med; 2022 Dec; 5(4):pbac030. PubMed ID: 36519139
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy.
Pal S; Nandi M; Dey D; Chakraborty BC; Shil A; Ghosh S; Banerjee S; Santra A; Ahammed SKM; Chowdhury A; Datta S
Aliment Pharmacol Ther; 2019 May; 49(10):1346-1359. PubMed ID: 30982998
[TBL] [Abstract][Full Text] [Related]
16. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.
Martin P; Lau DT; Nguyen MH; Janssen HL; Dieterich DT; Peters MG; Jacobson IM
Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2071-87.e16. PubMed ID: 26188135
[TBL] [Abstract][Full Text] [Related]
17. Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone.
Ren S; Wang W; Lu J; Wang K; Ma L; Zheng Y; Zheng S; Chen X
Front Immunol; 2022; 13():1035923. PubMed ID: 36389814
[TBL] [Abstract][Full Text] [Related]
18. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
[TBL] [Abstract][Full Text] [Related]
19. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.
Rapti I; Hadziyannis S
World J Hepatol; 2015 May; 7(8):1064-73. PubMed ID: 26052395
[TBL] [Abstract][Full Text] [Related]
20. [Natural History and Treatment Indications of Chronic Hepatitis B].
Sinn DH
Korean J Gastroenterol; 2019 Nov; 74(5):245-250. PubMed ID: 31765552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
